{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T03:17:32Z","timestamp":1783135052657,"version":"3.54.6"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3402400"],"award-info":[{"award-number":["2023YFC3402400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bmc.2026.118679","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T16:45:32Z","timestamp":1777308332000},"page":"118679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis and biological evaluation of 2,4,5-trisubstituted 7H-Pyrrolo[2,3-d]pyrimidine derivatives as potent EGFR tyrosine kinase inhibitors against the C797S acquired resistance mutation"],"prefix":"10.1016","volume":"139","author":[{"given":"Hao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianlong","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xishuang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixiao","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongying","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingchun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guimin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2026.118679_bb0005","series-title":"Global Cancer Observatory: Cancer Today (Version 1.1)","author":"Ferlay","year":"2024"},{"issue":"1","key":"10.1016\/j.bmc.2026.118679_bb0010","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"10299","key":"10.1016\/j.bmc.2026.118679_bb0015","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2026.118679_bb0020","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.bmc.2026.118679_bb0025","doi-asserted-by":"crossref","first-page":"6391","DOI":"10.3390\/jcm13216391","article-title":"EGFR-targeted therapies: a literature review","volume":"13","author":"Sha","year":"2024","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.bmc.2026.118679_bb0030","article-title":"Real-world evidence of EGFR targeted therapy in NSCLC- a brief report of decade long single center experience","volume":"4","author":"Chougule","year":"2023","journal-title":"JTO Clin Res Rep"},{"issue":"3","key":"10.1016\/j.bmc.2026.118679_bb0035","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3892\/ol.2024.14855","article-title":"Patients with non-small cell lung cancer with the exon 21 L858R mutation: from distinct mechanisms to epidermal growth factor receptor tyrosine kinase inhibitor treatments (review)","volume":"29","author":"Liu","year":"2025","journal-title":"Oncol Lett"},{"issue":"1","key":"10.1016\/j.bmc.2026.118679_bb0040","doi-asserted-by":"crossref","first-page":"195","DOI":"10.21037\/tlcr-23-680","article-title":"Subtype of EGFR exon 19 deletion mutations","volume":"13","author":"Fujimoto","year":"2024","journal-title":"Transl Lung Cancer Res"},{"issue":"2","key":"10.1016\/j.bmc.2026.118679_bb0045","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/1878-0261.13327","article-title":"Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real-world genomic datasets","volume":"17","author":"Viteri","year":"2023","journal-title":"Mol Oncol"},{"issue":"4","key":"10.1016\/j.bmc.2026.118679_bb0050","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.21037\/tcr.2020.03.10","article-title":"EGFR exon 20 insertion mutations in non-small cell lung cancer","volume":"9","author":"Wang","year":"2020","journal-title":"Transl Cancer Res"},{"issue":"2","key":"10.1016\/j.bmc.2026.118679_bb0055","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11523-022-00868-z","article-title":"Prevalence of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer in europe: a pragmatic literature review and meta-analysis","volume":"17","author":"Van Sanden","year":"2022","journal-title":"Target Oncol"},{"issue":"5","key":"10.1016\/j.bmc.2026.118679_bb0060","first-page":"1459","article-title":"Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor","volume":"7","author":"Ciardiello","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.bmc.2026.118679_bb0065","first-page":"1879","article-title":"Molecular targeted therapy--non-small-cell lung cancer and gefitinib","volume":"32","author":"Shimizu","year":"2005","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.bmc.2026.118679_bb0070","doi-asserted-by":"crossref","unstructured":"Mok, T. S.; Wu, Yi L.; Thongprasert, S.; Yang, C. H.; Chu, D. T.; Saijo, N.; Sunpaweravong, P.; Han, B.; Margono, B.; Ichinose, Y.; Nishiwaki, Y.; Ohe, Y.; Yang, J. J.; Chewaskulyong, B.; Jiang, H.; Duffield, E. L.; Watkins, C. L.; Armour, A. A.; Fukuoka, M. Gefitinib or Carboplatin\u2013Paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361 (10), 947\u2013957. DOI: https:\/\/doi.org\/10.1056\/nejmoa0810699.","DOI":"10.1056\/NEJMoa0810699"},{"key":"10.1016\/j.bmc.2026.118679_bb0075","doi-asserted-by":"crossref","unstructured":"Mitsudomi, T.; Morita, S.; Yatabe, Y.; Negoro, S.; Okamoto, I.; Tsurutani, J.; Seto, T.; Satouchi, M.; Tada, H.; Hirashima, T.; Asami, K.; Katakami, N.; Takada, M.; Yoshioka, H.; Shibata, K.; Kudoh, S.; Shimizu, E.; Saito, H.; Toyooka, S.; Nakagawa, K.; Fukuoka, M. Gefitinib versus Cisplatin plus Docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11 (2), 121\u2013128. DOI: https:\/\/doi.org\/10.1016\/s1470-2045(09)70364-x.","DOI":"10.1016\/S1470-2045(09)70364-X"},{"key":"10.1016\/j.bmc.2026.118679_bb0080","doi-asserted-by":"crossref","unstructured":"Maemondo, M.; Inoue, A.; Kobayashi, K.; Sugawara, S.; Oizumi, S.; Isobe, H.; Gemma, A.; Harada, M.; Yoshizawa, H.; Kinoshita, I.; Fujita, Y.; Okinaga, S.; Hirano, H.; Yoshimori, K.; Harada, T.; Ogura, T.; Ando, M.; Miyazawa, H.; Tanaka, T.; Saijo, Y.; Hagiwara, K.; Morita, S.; Nukiwa, T.; North-East Japan Study, Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362 (25), 2380\u20132388. DOI: https:\/\/doi.org\/10.1056\/nejmoa0909530.","DOI":"10.1056\/NEJMoa0909530"},{"issue":"5","key":"10.1016\/j.bmc.2026.118679_bb0085","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1158\/1078-0432.CCR-10-2277","article-title":"Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay","volume":"17","author":"Arcila","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.bmc.2026.118679_bb0090","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.bmc.2026.118679_bb0095","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.critrevonc.2013.06.009","article-title":"Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma","volume":"88","author":"Cadranel","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"issue":"34","key":"10.1016\/j.bmc.2026.118679_bb0100","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","article-title":"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.bmc.2026.118679_bb0105","first-page":"285","article-title":"Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer","volume":"7","author":"Yap","year":"2014","journal-title":"Pharmgenomics Pers Med"},{"issue":"90","key":"10.1016\/j.bmc.2026.118679_bb0110","doi-asserted-by":"crossref","first-page":"90ra59","DOI":"10.1126\/scitranslmed.3002356","article-title":"Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling","volume":"3","author":"Chmielecki","year":"2011","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.bmc.2026.118679_bb0115","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1158\/1535-7163.MCT-11-0750","article-title":"The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor","volume":"11","author":"Kim","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.bmc.2026.118679_bb0120","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-015-0533-4","article-title":"Osimertinib: first global approval","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.bmc.2026.118679_bb0125","first-page":"109","article-title":"Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy","volume":"8","author":"Santarpia","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bmc.2026.118679_bb0130","doi-asserted-by":"crossref","unstructured":"Cross, D. A.; Ashton, S. E.; Ghiorghiu, S.; Eberlein, C.; Nebhan, C. A.; Spitzler, P. J.; Orme, J. P.; Finlay, M. R.; Ward, R. A.; Mellor, M. J.; Hughes, G.; Rahi, A.; Jacobs, V. N.; Red Brewer, M.; Ichihara, E.; Sun, J.; Jin, H.; Ballard, P.; Al-Kadhimi, K.; Rowlinson, R.; Klinowska, T.; Richmond, G. H.; Cantarini, M.; Kim, D. W.; Ranson, M. R.; Pao, W. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014, 4 (9), 1046\u20131061. DOI: https:\/\/doi.org\/10.1158\/2159-8290.cd-14-0337.","DOI":"10.1158\/2159-8290.CD-14-0337"},{"issue":"6","key":"10.1016\/j.bmc.2026.118679_bb0135","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non\u2013small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat Med"},{"issue":"17","key":"10.1016\/j.bmc.2026.118679_bb0140","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-0560","article-title":"The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies","volume":"21","author":"Niederst","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2026.118679_bb0145","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.lungcan.2020.07.014","article-title":"Mechanisms of osimertinib resistance and emerging treatment options","volume":"147","author":"Schmid","year":"2020","journal-title":"Lung Cancer"},{"issue":"17","key":"10.1016\/j.bmc.2026.118679_bb0150","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1007\/s40265-021-01632-9","article-title":"Mobocertinib: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.bmc.2026.118679_bb0155","doi-asserted-by":"crossref","unstructured":"Gonzalvez, F.; Vincent, S.; Baker, T. E.; Gould, A. E.; Li, S.; Wardwell, S. D.; Nadworny, S.; Ning, Y.; Zhang, S.; Huang, W.; Hu, Y.; Li, F.; Greenfield, M. T.; Zech, S. G.; Das, B.; Narasimhan, N. I.; Clackson, T.; Dalgarno, D.; Shakespeare, W. C.; Fitzgerald, M.; Chouitar, J.; Griffin, R. J.; Liu, S.; Wong, K.; Zhu, X.; Rivera, V. M. Mobocertinib (TAK-788): a targeted inhibitor of EGFRExon 20 insertion mutants in Non\u2013Small Cell Lung Cancer. Cancer Discov 2021, 11 (7), 1672\u20131687. DOI: https:\/\/doi.org\/10.1158\/2159-8290.cd-20-1683.","DOI":"10.1158\/2159-8290.CD-20-1683"},{"key":"10.1016\/j.bmc.2026.118679_bb0160","series-title":"Takeda provides update on EXKIVITY\u00ae (mobocertinib)","year":"2023"},{"issue":"3","key":"10.1016\/j.bmc.2026.118679_bb0165","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13766","article-title":"Mobocertinib: mechanism of action, clinical, and translational science","volume":"17","author":"Hanley","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"7605","key":"10.1016\/j.bmc.2026.118679_bb0170","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.bmc.2026.118679_bb0175","doi-asserted-by":"crossref","first-page":"5613","DOI":"10.1021\/acs.jmedchem.7b00316","article-title":"Trisubstituted pyridinylimidazoles as potent inhibitors of the clinically resistant L858R\/T790M\/C797S EGFR mutant: targeting of both hydrophobic regions and the phosphate binding site","volume":"60","author":"Gunther","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118679_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111888","article-title":"Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R\/T790M\/C797S mutant EGFR tyrosine kinase inhibitors","volume":"186","author":"Lei","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118679_bb0185","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejmech.2018.02.051","article-title":"Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs","volume":"148","author":"Zhang","year":"2018","journal-title":"Eur J Med Chem"},{"issue":"46","key":"10.1016\/j.bmc.2026.118679_bb0190","doi-asserted-by":"crossref","first-page":"10789","DOI":"10.1039\/C9SC03445E","article-title":"Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M\/C797S","volume":"10","author":"Lategahn","year":"2019","journal-title":"Chem Sci"},{"key":"10.1016\/j.bmc.2026.118679_bb0195","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14768","article-title":"Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer","volume":"8","author":"Uchibori","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2026.118679_bb0200","series-title":"Aryl-Phosphorus-Oxygen Compound as EGFR Kinase Inhibitor","volume":"WO2019015655A1","author":"Wu","year":"2018"},{"issue":"14","key":"10.1016\/j.bmc.2026.118679_bb0205","doi-asserted-by":"crossref","first-page":"9662","DOI":"10.1021\/acs.jmedchem.2c00704","article-title":"Discovery of BLU-945, a reversible, potent, and wild-type-sparing next-generation EGFR mutant inhibitor for treatment-resistant non-small-cell lung cancer","volume":"65","author":"Eno","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118679_bb0210","doi-asserted-by":"crossref","first-page":"9156","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9156","article-title":"A phase 1\/2 study of BLU-945 in patients with common activating EGFR-mutant non\u2013small cell lung cancer (NSCLC): SYMPHONY trial in progress","volume":"40","author":"Shum","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2026.118679_bb0215","doi-asserted-by":"crossref","unstructured":"Elamin, Y. Y.; Nagasaka, M.; Shum, E.; Bazhenova, L.; Camidge, D. R.; Cho, B. C.; Felip, E.; Goto, K.; Lin, C. C.; Piotrowska, Z.; Planchard, D.; Rotow, J. K.; Spigel, D. R.; Tan, D. S.; Yoshida, T.; Minchom, A. R.; De Langen, A.; Kato, T.; Zalutskaya, A.; Reckamp, K. L. BLU-945 monotherapy and in combination with osimertinib (OSI) in previously treated patients with advanced EGFR-mutant (EGFRm) NSCLC in the phase 1\/2 SYMPHONY study. J Clin Oncol 2023, 41, 9011\u20139011. DOI: https:\/\/doi.org\/10.1200\/jco.2023.41.16_suppl.9011.","DOI":"10.1200\/JCO.2023.41.16_suppl.9011"},{"issue":"11","key":"10.1016\/j.bmc.2026.118679_bb0220","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1158\/1535-7163.MCT-16-0281","article-title":"AC0010, an irreversible EGFR inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance in animal models and lung cancer patients","volume":"15","author":"Xu","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"10.1016\/j.bmc.2026.118679_bb0225","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1016\/j.bmc.2018.05.039","article-title":"Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido[3,4-d]pyrimidine scaffold","volume":"26","author":"Zhang","year":"2018","journal-title":"Bioorg Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:27:54Z","timestamp":1783132074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626001355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":45,"alternative-id":["S0968089626001355"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118679","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of 2,4,5-trisubstituted 7H-Pyrrolo[2,3-d]pyrimidine derivatives as potent EGFR tyrosine kinase inhibitors against the C797S acquired resistance mutation","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118679","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"118679"}}